Efficacy and safety of zilebesiran in adults with hypertension: a systematic review and meta-analysis of randomized controlled trials.
Eur J Clin PharmacolSep 16, 2026 (epub)
Muhammad Hussain, Muhammad Hassan, Asharib Sohaib et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the efficacy and safety of zilebesiran in 1,412 adults with mild to moderate hypertension. The primary outcome showed a placebo-adjusted reduction in office systolic blood pressure of -7.16 mmHg (95% CI: -13.63 to -0.70). Zilebesiran demonstrated significant reductions in various blood pressure measures, although adverse events were more frequent compared to placebo.
Key findings
- Zilebesiran reduced office systolic blood pressure by -7.16 mmHg compared to placebo.
- 24-hour ambulatory systolic blood pressure decreased by -9.92 mmHg with zilebesiran.
- Adverse events occurred more frequently with zilebesiran, with an odds ratio of 1.46.
- Daytime systolic blood pressure reduction was greater at 3 months than at 6 months.
Why it matters
Hypertension is a significant risk factor for cardiovascular disease, and effective management is crucial. Zilebesiran shows promise in reducing blood pressure, which may enhance treatment options for patients with hypertension.